Mesoblast Limited - American Depositary Shares (MESO) closed at $15.67 on October 29, 2026, up 17.0% from the previous close, on volume of 612,000 shares (30-day average 253,702).
Data as of October 29, 2026.
Market Chameleon (Thu, 29-Oct 4:32 AM ET)
Mesoblast Posts Strong Q1 FY2027 Revenue and Cash Gains, Advances Late-Stage Cell Therapy Trials
TipRanks (Thu, 29-Oct 7:20 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 29-Oct 7:04 AM ET)
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Globe Newswire (Wed, 28-Oct 8:19 PM ET)
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Globe Newswire (Thu, 24-Sep 7:00 AM ET)
Mesoblast Reports Substantial Revenue Growth to US$120M
Globe Newswire (Wed, 26-Aug 8:32 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Globe Newswire (Sun, 16-Aug 8:35 PM ET)
Globe Newswire (Wed, 29-Jul 8:57 PM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of October 29, 2026, MESO stock price climbed to $15.67 with 612,000 million shares trading.
MESO has a beta of 1.89, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.20 to the broad based SPY ETF.
MESO has a market cap of $2.03 billion. This is considered a Mid Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $120 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-61 million and exceeded earnings estimates by $.46.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, QQQS, IBBQ, BIB.
MESO has underperformed the market in the last year with a return of -6.3%, while SPY returned +13.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MESO shares. However, MESO has outperformed the market in the last 3 month and 2 week periods, returning +8.4% and +13.6%, while SPY returned +4.1% and 0.0%, respectively. This indicates MESO has been having a stronger performance recently.
MESO support price is $12.97 and resistance is $13.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.
